Cite
HARVARD Citation
Garcia‐Manero, G. et al. (2017). Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes. Cancer. 123 (6), pp. 994-1002. [Online].